Kim A Reiss (Reiss Binder), MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Assistant Program Director , Hematology/Oncology Fellowship at University of Pennsylvania
Member, Abramson Cancer Center
Co-Leader, Cancer Therapeutics Program, University of Pennsylvania
Physician Lead, Pancreatic Cancer Clinical Research Unit, University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-360-0735
Fax: 215-662-4646
Fax: 215-662-4646
Education:
BA (Psychology)
Colby College, 2002.
Post BA (Pre-Med)
Johns Hopkins University , 2003.
MD (Medicine)
Penn State College of Medicine , 2008.
Permanent linkBA (Psychology)
Colby College, 2002.
Post BA (Pre-Med)
Johns Hopkins University , 2003.
MD (Medicine)
Penn State College of Medicine , 2008.
Selected Publications
Alison M. Schram, Olumide B. Gbolahan, Cindy Neuzillet, Dirk Arnold, Antoine Hollebecque, Richard Greil, Mohammed Najeeb Al Hallak Jordi Rodon Ahnert, Kim A. Reiss, Paul F. La Porte, Tormod Kyrre Guren, Carolyn E. Ragsdale, Fiona Garner, Alejandro D. Ricart, Shola Adeyemi,13 Christoph Springfeld : Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: analysis from the phase 2 eNRGy trial. ASCO GI 2026, San Francisco, CA Jan 2026.Ben Boursi, MD; Zakary L. Kolkey, MD; Kim Anna Reiss, MD; Mark H. O’Hara, MD; William Chapin, MD, MSCE : Comparative effectiveness of oxaliplatin or irinotecan rechallenge/reintroduction vs standard third-line therapies in patients with metastatic colorectal cancer. ASCO GI 2026, San Francisco, CA Jan 2026.
Emmanuel S. Antonarakis, Katherine L. Nathanson, Kim A. Reiss, Colin C. Pritchard, Jacob E. Berchuck, Kimberly Johnson, Derek W. Brown, Hanna Tukachinsky: CH mutations in 16,812 advanced cancer patients: Overestimation of CH-derived BRCA1/2 variants detected on liquid biopsy (Letter). Clinical Cancer Research Aug 2025.
Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson Susan M. Domchek, Kim A. Reiss: LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. JCO Precision Oncology Jul 2025.
Susan M. Domchek, Alex Torres, Megan Aaron-Ocko, JoAnn Miller, Phil Seger, Hayley Knollman, Kim Reiss, Payal D. Shah, Matthew Morrow, Jeffrey Skolnik, Robert H. Vonderheide: Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with BRCA1/2 mutations. Oral Abstract Session, ASCO 2025, Chicago, IL June 2025.
Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss: LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes. ASCO 2025, Chicago, IL June 2025.
Uri Amit MD MPH PhD, James M Metz MD, John P Plastaras MD PhD, Rohi Gheewala MD, Peter O’Dwyer MD, Ursina Teitelbaum MD, Nevena Damjanov MD, Charles Vollmer MD, Charles J Schneider MD, Major Kenneth Lee IV, MD, PhD, Mark O’Hara MD, Kim A. Reiss MD, Erica L Carpenter PhD, Thomas B Karasic MD, Andre Konski MD, Rosmarie Mick, Paul Wileyto PhD and Edgar Ben-Josef MD: A Phase I Dual Dose Escalation Study of Radiation and Nab-paclitaxel in Patients with Unresectable and Borderline Resectable Pancreatic Cancer. Cancer June 2025.
Bever KM, Durham JN, Qi H, Azad NS, Laheru D, Fisher GA, Greten TF, Hays J, Krishnamurthy A, Reiss KA, Sanborn R, Wang H, Diaz LA, Le DT: 10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors (KEYNOTE-016). Rapid Oral Abstract Session, ASCO 2025, Chicago, IL June 2025.
Kim A. Reiss , Katherine Nathanson , Alexa B. Schrock, Alexander D. Fine, Derek W. Brown, Brennan Decker, Jason Hughes, Chang Xu, Bahar Yilmazel, Rebecca Hodges, Kimberly Johnson, Amaya Gasco, Hanna Tukachinsky: BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC). ASCO 2025, Chicago IL June 2025.
Kim A. Reiss MD, Kevin C Soares MD, MS, Robert J Trophy MD, PhD, Bishal Gyawali, MD, PhD, FASCO: Treatment innovations in pancreatic cancer: putting patient priorities first. ASCO Educational Book Apr 2025.